Dr. Thomas L. Ashcom, M.D., PH.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,521
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: Jefferson Medical College of Thomas Jefferson University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
KS license 0424024
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ascension Via Christi Hospitals Wichita, Inc. Wichita, KS
- University of Ks Hlth System Great Bend Campus Great Bend, KS
- Pratt Regional Medical Center Pratt, KS
- Kansas Heart Hospital Wichita, KS
- Medicine Lodge Memorial Hospital Medicine Lodge, KS
Medical groups
- Kansas Heart Hospital, LLC (27 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,521
- Services billed
- 7,278
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,420 | 925 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 660 | 254 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 657 | 254 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 539 | 266 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 524 | 493 |
| Injection, regadenoson, 0.1 mg | 428 | 106 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 303 | 298 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 265 | 261 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 262 | 34 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 257 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Wichita, KS | 1,558 |
| Amlodipine Besylate Other prescribers in Wichita, KS | 1,123 |
| Carvedilol Other prescribers in Wichita, KS | 1,024 |
| Diltiazem 24hr Er (Cd) (diltiazem hcl) Other prescribers in Wichita, KS | 975 |
| Eliquis (apixaban) Other prescribers in Wichita, KS | 942 |
| Metoprolol Tartrate Other prescribers in Wichita, KS | 936 |
| Metoprolol Succinate Other prescribers in Wichita, KS | 907 |
| Lisinopril Other prescribers in Wichita, KS | 787 |
| Potassium Chloride Other prescribers in Wichita, KS | 535 |
| Losartan Potassium Other prescribers in Wichita, KS | 529 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 30 payments worth $832 in total to this clinician.
| Food and Beverage | $744 |
|---|---|
| Gift | $88.33 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Medtronic, Inc. Nov 4, 2025 | Gift MICRA · Pacemakers · in-kind | $88.33 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $43,695 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and em…
Boehringer Ingelheim Pharma GmbH & Co.kg - Dapagliflozin in Acute Decompensated Heart Failure
AstraZeneca Pharmaceuticals LP - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly…
Amgen Inc. - EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and em…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.